Vivos Therapeutics (VVOS) Gross Margin (2020 - 2026)

Vivos Therapeutics (VVOS) has reported Gross Margin for 7 consecutive years, with 57.31% the latest figure, recorded in Q2 2026.

• On a quarterly basis, Gross Margin rose 207.0% year-over-year to 57.31% in Q2 2026; TTM through Jun 2026 was 61.9%, a 597.0% increase from a year earlier, with the FY2025 full-year figure at 60.44%, up 43.0% from the prior year.
• Gross Margin was 57.31% for Q2 2026 at Vivos Therapeutics, down from 59.5% in the prior quarter.
• Over five years, Gross Margin peaked at 78.14% in Q4 2025 and troughed at 50.03% in Q1 2025.
• A 5-year average of 60.45% and a median of 59.93% in 2022 frame the typical range for Gross Margin.
• Across the five-year window, Gross Margin sank 1873 bps in 2022 and surged 2143 bps in 2025, its largest moves.
• Over 5 years, Gross Margin stood at 60.35% in 2022, then gained by 7 bps to 64.32% in 2023, then decreased by 12 bps to 56.71% in 2024, then surged by 38 bps to 78.14% in 2025, then decreased by 27 bps to 57.31% in 2026.
• The last three Gross Margin figures came in at 57.31% (Q2 2026), 59.5% (Q1 2026), and 78.14% (Q4 2025), per Business Quant data.